Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 37

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 37
---
 activities. With respect
to such grants, we are committed to pay royalties at a rate of 3.0% to 3.5% on sales proceeds up to the total amount of grants received,
linked to the U.S. dollar and bearing interest at an annual rate of LIBOR applicable to dollar deposits. Until October 25, 2023, the
interest was calculated at a rate based on 12-month LIBOR applicable to U.S. Dollar deposits. However, on October 25, 2023, the IIA published
a directive concerning changes in royalties to address the expiration of the LIBOR. Under such directive, regarding IIA grants approved
by the IIA prior to January 1, 2024 but which are outstanding thereafter, as of January 1, 2024 the annual interest is calculated at
a rate based on 12-month SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%; and, for grants approved on or
following January 1, 2024, the annual interest shall be the higher of (i) the 12 months SOFR interest rate, plus 1%, or (ii) a fixed
annual interest rate of 4%. Even after payment in full of these amounts, we will still be required to comply with the requirements of
the Israeli Encouragement of Industrial Research, Development and Technological Innovation Law, 1984, or the R&D Law, and related
regulations, with respect to those past grants. When a company develops know-how, technology or products using IIA grants, the terms
of these grants and the R&D Law restrict the transfer outside of Israel of such know-how, and of the manufacturing or manufacturing
rights of such products, technologies or know-how, without the prior approval of the IIA. Therefore, if aspects of our technologies are
deemed to have been developed with IIA funding, the discretionary approval of an IIA committee would be required for any transfer to
third parties outside of Israel of know-how or manufacturing or manufacturing rights related to those aspects of such technologies. Furthermore,
the IIA may impose certain conditions on any arrangement under which it permits us to transfer technology or development out of Israel
or may not grant such approvals at all.

Furthermore, the consideration available to our
shareholders in a future transaction involving the transfer outside of Israel of technology or know-how developed with IIA funding (such
as a merger or similar transaction) may be